Schutte Andrew 13D and 13G filings for RepliCel Life Sciences Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-04-20 1:03 pm Purchase | 2023-03-14 | 13D | RepliCel Life Sciences Inc. REPCF | Schutte Andrew | 25,104,422 34.530% | 6,480,416 (+34.80%) | Filing |
| 2023-01-26 10:50 am Purchase | 2022-12-30 | 13D | RepliCel Life Sciences Inc. REPCF | Schutte Andrew | 18,624,006 31.170% | 10,272,471 (+123.00%) | Filing |
| 2022-06-02 1:39 pm Purchase | 2022-05-04 | 13D | RepliCel Life Sciences Inc. REPCF | Schutte Andrew | 8,351,535 18.550% | 3,724,184 (+80.48%) | Filing |